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Pazopanib in advanced soft tissue sarcomas
Alex T. J. Lee1,2, Robin L. Jones2,3 and Paul H. Huang1
Pazopanib is the ﬁrst and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of
soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical
work indicates that pazopanib exerts an anticancer effect through the inhibition of both angiogenic and oncogenic signaling
pathways. Following the establishment of optimal dosing and safety proﬁles in early phase studies and approval for the treatment
of advanced renal cell carcinoma, pazopanib was investigated in STS. A landmark phase III randomized study demonstrated
improved progression-free survival with pazopanib compared to that with placebo in pretreated patients with STS of various
subtypes. The efﬁcacy of pazopanib in speciﬁc STS subtypes has been further described in real-world-based case series in both
mixed and subtype-speciﬁc STS cohorts. At present, there are no clinically validated predictive biomarkers for use in selecting
patients with advanced STS for pazopanib therapy, limiting the clinical effectiveness and cost-effectiveness of the drug. In this
review, we summarize the preclinical and clinical data for pazopanib, outline the evidence base for its effect in STS and explore
reported studies that have investigated putative biomarkers.
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INTRODUCTION
Pazopanib is an oral multitarget tyrosine kinase inhibitor (TKI) with
a clinical antitumor effect that is thought to be exerted through its
selective inhibition of vascular endothelial growth factor receptor
(VEGFR)-mediated angiogenesis, as well as its direct blockade of
growth-promoting receptor tyrosine kinases (RTKs), including
platelet-derived growth factor receptors (PDGFRs), ﬁbroblast
growth factor receptors (FGFRs), and KIT1–5. After receiving
marketing authorization for the treatment of metastatic renal cell
carcinoma (mRCC), pazopanib became the ﬁrst (and currently
only) TKI licensed for the treatment of multiple subtypes of
advanced soft tissue sarcoma (STS). This approval was based on
the results of a double-blind, placebo-controlled randomized
phase III trial that demonstrated signiﬁcant prolongation of
progression-free survival (PFS) in patients with pretreated
advanced STS who received pazopanib6. However, despite this
evidence of an antitumor effect, no signiﬁcant difference in overall
survival (OS) was observed between pazopanib and placebo-
treated patients. The failure of PFS gain to translate to OS beneﬁt
has adversely inﬂuenced the cost assessment of pazopanib for this
indication, leading to funding limitations in certain health
economies worldwide7–9. There is currently a poor understanding
of the clinical mechanisms of pazopanib response and resistance
and an unmet need for predictive biomarkers that are able to
prospectively select the subgroup of STS patients most likely to
beneﬁt from pazopanib, thus improving the clinical efﬁciency of
the drug. In this review, we summarize the preclinical and early
clinical development of pazopanib, explore the evidence for
efﬁcacy in STS and outline reported data resulting from efforts to
identify biomarkers for pazopanib response.
PRECLINICAL DEVELOPMENT OF PAZOPANIB
Pazopanib was identiﬁed through the chemical screening of
compounds for inhibition of VEGFR2, a key mediator of tumor
angiogenesis10. After identiﬁcation of an initial lead compound as
an inhibitor of VEGFR2 by using a direct kinase activity assay,
chemical optimization was undertaken to increase the inhibitory
potency and improve the pharmacokinetic (PK) proﬁle in mouse
models. Optimized molecules were also shown to have inhibitory
potency against VEGFR1 and VEGFR3, as well as other closely-
related RTKs, including PDGFRB, KIT, FGFR1, and colony-
stimulating factor 1 receptor (CSF1R). This study and further
reports on the kinase inhibitory proﬁle of pazopanib are
summarized in Fig. 11–3. Pharmacodynamic (PD) studies of the
biological activity of the drug were performed in a range of
in vitro and in vivo assays3. Treatment of cultured human
umbilical vein endothelial cells (HUVECs) with pazopanib resulted
in potent inhibition of VEGF-mediated phosphorylation of VEGFR2,
with associated inhibition of HUVEC proliferation. In vitro
inhibition of ligand-mediated phosphorylation of KIT and PDGFRB
by pazopanib was also shown in human lung cancer and foreskin
ﬁbroblast cells, respectively, although the drug had no effect on
proliferation in an unspeciﬁed panel of tumor cells. Inhibition of
angiogenesis was demonstrated in a mouse model of ocular
angiogenesis and subcutaneous implantation of a ligand-
containing Matrigel plug. Administration of oral pazopanib to
immunocompromised mice was associated with dose-dependent
inhibition of growth of established xenografts of human color-
ectal, melanoma, prostate, breast, kidney, and breast cancer cell
lines. A steady-state plasma concentration was shown to provide
optimal in vivo inhibition of VEGFR2 phosphorylation, angiogen-
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esis, and xenograft growth, with a strong correlation between
inhibition of VEGFR2 kinase activity and antitumor effect in
xenografts.
Further preclinical evidence has indicated that the antitumor
effect of pazopanib may not solely be mediated by inhibition of
angiogenesis but may also be mediated through a direct effect on
tumor cells. A study investigating the effect of pazopanib in
human multiple myeloma models found that, in addition to the
inhibition of endothelial cell proliferation and in vivo tumor
angiogenesis, the drug also had direct antiproliferative and
proapoptotic effects on tumor cells and xenografts5. This effect
on myeloma cells correlated with downregulation of several
cancer-related genes involved in pathways including cytokine and
chemokine signaling, cell cycle, and insulin receptor pathways, as
well as upregulation of proapoptotic genes. Pazopanib has been
shown across a series of studies to act as a pan-RAF inhibitor and
to exert an anticancer effect through inhibition of MAPK pathway
signaling in cancer cells in the absence of a demonstrable
antiangiogenic effect11. In in vivo and xenograft models of a brain-
tropic Her2-positive, BRAF-mutated breast cancer cell line,
pazopanib prevented the growth of brain metastasis in associa-
tion with reduced MAPK pathway activation but no change in
markers of angiogenesis. A later study in the same breast cancer
xenograft model showed that the inhibition of brain metastasis
growth by pazopanib was accompanied by a reduction in the
number of PDGFRB-expressing, metastasis-associated astrocytes,
suggesting a possible role for pazopanib-mediated therapeutic
modulation of the tumor microenvironment (TME)12. In follow-on
studies, a panel of breast cancer and melanoma cell lines with
varying BRAF mutational status were used in orthotopic xenograft
models that were then treated with pazopanib13. Here, xenografts
with either wildtype or exon-11-mutated BRAF showed signiﬁcant
sensitivity to pazopanib and a corresponding reduction of MAPK
pathway activation in tumor cells and reduced angiogenesis.
Collectively, these preclinical data demonstrate that pazopanib is
a potent inhibitor of several key kinases involved in angiogenic and
oncogenic pathways, with an antitumor effect that is mediated by
both antiangiogenic and direct anticancer cell activity.
EARLY PHASE CLINICAL DEVELOPMENT OF PAZOPANIB
Based on these preclinical ﬁndings of antitumour effects and
proposed optimal dosing, a phase I trial of pazopanib was
performed, with 43 patients enrolled in an initial dose-escalation
phase and a further 20 patients in a subsequent dose-expansion
phase14. PK assessment identiﬁed that steady-state exposure was
achieved at doses of 800mg or more as a once daily oral dose. In
line with toxicities observed with other antiangiogenic TKIs,
hypertension was the most common adverse event (grade 3 in
25%), followed by diarrhea, hair depigmentation, nausea, anorexia,
and fatigue. Proteinuria was the most common laboratory
abnormality (any grade seen in 52% of patients), followed by a
range of cytopenias and blood biochemistry disturbances, which
were grade 1 and 2 in the large majority of affected patients. As no
maximally tolerated dose was identiﬁed, an oral dose of 800mg
once daily was selected for further studies because doses > 800mg
did not increase drug exposure.
PD analyses in this phase I study demonstrated that plasma
VEGF concentrations increased by more than three-fold in ~50%
of treated patients following drug initiation. In a subset of
patients who underwent dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI), 7/12 (58%) patients were seen to
have a >50% reduction in tumor blood ﬂow at Day 8 of
treatment, and 10/11 (91%) at Day 22. The incidence of
hypertension was associated with higher trough drug levels on
Day 22 of therapy, suggesting that hypertension may act as a PD
marker of pazopanib activity.
Assessment of preliminary clinical activity in this study recorded
a partial response by RECIST criteria in three patients (two with
mRCC and one with pancreatic adenocarcinoma), while stable
disease of at least 6 months duration was observed in 14 patients
—of note, among these were two patients with chondrosarcoma,
one with leiomyosarcoma (LMS), and one with a gastrointestinal
stromal tumor (GIST). A further phase I trial to assess PK and PD in
53 patients aged 2–22 years was also undertaken and demon-
strated a similar toxicity proﬁle to that seen in adult patients, with
one patient with occult brain metastasis experiencing intracranial
bleeding15. All patients who underwent DCE-MRI evaluation of
tumor vascular dynamics demonstrated decreases in tumor blood
ﬂow and permeability, while two objective partial responses (one
with desmoplastic small round cell tumor (DSRCT)) and stable
disease of >6 months in eight patients (seven with sarcomas) were
observed.
Fig. 1 Kinase inhibitory proﬁle of pazopanib. The bar graph
indicates the kinase inhibitory concentration (IC50—drug concen-
tration at which 50% of the target enzymatic activity is inhibited in a
cell-free kinase assay) of pazopanib, as reported by Kumar et al.3
Involvement of kinases in canonical oncogenic processes/pathways
is indicated in the table on the left (GO.0001525—angiogenesis;
GO.0043410—positive regulation of MAPK cascade; GO.0014068—
positive regulation of phosphatidylinositol 3-kinase signaling;
GO:0046427—positive regulation of the JAK-STAT cascade;
GO.0045740—positive regulation of DNA replication)
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Based on these phase I data, pazopanib was deemed to be a
safe and generally well-tolerated drug with an optimal oral dose of
800mg once daily. Early evidence of clinical efﬁcacy prompted
further development in mRCC, a cancer with a well-described
central role of angiogenesis in tumor development. Subsequent
randomized phase III trials in mRCC demonstrated superior PFS
with pazopanib vs. placebo in pretreated patients and noninferior
disease control and survival. In addition, pazopanib showed
favorable quality-of-life outcomes compared to sunitinib, another
antiangiogenic TKI already approved for ﬁrst line treatment16,17.
These studies established pazopanib as a standard of care in
mRCC while also providing further data on drug toxicity,
conﬁrming severe hypertension as a commonly encountered
adverse effect, as well as signiﬁcant neutropenia and/or liver
enzyme derangement in ~10% of patients.
CLINICAL DEVELOPMENT OF PAZOPANIB FOR ADVANCED STS
As a result of the evidence of durable disease stabilization seen in
4/9 patients with sarcomas treated with pazopanib in the initial
phase I trial, further development of the drug in these diseases
was pursued.
EORTC noncomparative phase II trial
A noncomparative phase II trial of pazopanib was undertaken by
the European Organization for Research and Treatment of Cancer
(EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) in patients
with advanced intermediate or high-grade STS with conﬁrmed
disease progression, who were either ineligible for cytotoxic
chemotherapy or who had received fewer than three prior
cytotoxic agents for advanced disease18. Although this study
was nonrandomized, patients were prospectively stratiﬁed into
one of four histologically deﬁned strata: LMS, liposarcoma (LPS),
synovial sarcoma (SS) and a heterogeneous ‘other’ stratum. The
primary efﬁcacy endpoint was the progression-free rate at
12 weeks of treatment (12wPFR), with predeﬁned rates of 40%
and 20% determined as thresholds reﬂecting drug activity or
inactivity19. For each stratum, an initial enrollment of 17 evaluable
patients was to be treated at 800mg once daily until disease
progression, unacceptable toxicity, or withdrawal of consent. If 4/
17 patients experienced nonprogression at 12 weeks, that stratum
was expanded to a total accrual of 37 patients, and if 11 or more
out of 37 patients were progression-free, this would indicate that
further investigation of pazopanib in that stratum would be
warranted.
A total of 142 patients were treated within the study. In the LPS
arm, only 3 of the ﬁrst 17 patients showed nonprogression at
12 weeks, and thus, recruitment to this cohort was terminated due
to lack of activity. The three other arms continued to complete the
second stage of recruitment. Included among the 44 patients
recruited into the ‘other subtypes’ stratum were small numbers of
malignant peripheral nerve sheath tumors (MPNSTs), vascular
sarcomas, ﬁbrohistiocytic or ﬁbroblastic sarcomas, solitary ﬁbrous
tumors, rhabdomyosarcoma and GIST, as well as 19 tumors of
unspeciﬁed differentiation. Four out of 142 patients were
excluded from the efﬁcacy analysis due to lack of measurable
disease, change of diagnosis to GIST on central histopathology
review or lack of objective disease progression prior to
commencement of pazopanib. A further two patients were not
evaluable due to resection of the target lesion or withdrawal due
to coronary heart disease, resulting in a total of 136 patients
evaluable for efﬁcacy.
Although accrual of the LPS arm was stopped after the ﬁrst
stage, two patients who had initially been categorized into one of
the other three strata were found on central histopathology
review to have LPS. As both of these patients met the 12-week
progression-free endpoint, the overall 12wPFR in the LPS arm was
26% (5/19 patients). In the LMS, SS and ‘other’ strata, 12wPFR was
44% (18/41 patients), 49% (18/37), and 39% (16/41), respectively.
An objective partial response was seen in 9/136 patients (6.6%): 5
SS, 3 ‘other’, and 1 LMS. Of these patients, 4 (3 other, 1 SS)
experienced disease progression between 253 and 503 days after
treatment initiation, while the other 5 (1 LMS, 4 SS) were still
progression free at 415–812 days. The median PFS was 80, 91, 161,
and 91 days, and the median OS was 197, 354, 310, and 299 days
in the LPS, LMS, SS, and ‘other’ strata, respectively. These PFS and
OS rates compared favorably to the historic controls for LMS, SS,
and other subtype cohorts19.
PALETTE phase III randomized control trial (RCT)
Building on the results of the EORTC phase II study, the STBSG, in
collaboration with GlaxoSmithKline (the manufacturer of pazopa-
nib), undertook the Pazopanib explored in SofT-Tissue Sarcoma
(PALLETTE) study, a double-blinded, placebo-controlled phase III
RCT6. In this international, multicenter trial, adult patients with
progressing advanced STS were randomized on a 2:1 basis to
receive pazopanib 800mg once daily or placebo until disease
progression, unacceptable toxicity or patient withdrawal. On-trial
crossover to pazopanib was not permitted for patients who
progressed on placebo. Eligibility criteria stipulated that patients
must have received between 1 and 4 lines of previous systemic
therapy, including an anthracycline, for advanced disease. Most
common histological subtypes of STS were eligible for enrollment
—notably, based on the earlier phase II evidence of limited
activity, LPS was not included in this phase III trial. PFS was the
primary endpoint, with a sample size designed to provide 95%
power to detect a 15% difference in the progression-free rate at
6 months, corresponding to a hazard ratio of 0.63. This sample size
would also provide 90% power to detect HR 0.67 for OS, which
was included in secondary endpoints along with toxicity and
quality-of-life measures.
Between October 2008 and February 2010, 369 patients were
randomized, with 246 allocated to pazopanib and 123 allocated to
placebo. In the analysis of the intention-to-treat cohort, after a
median follow-up of 25 months, a clinically signiﬁcant 3-month
improvement in median PFS was seen with pazopanib (4.6 vs.
1.6 months; HR 0.31; 95% CI 0.24–0.40; p < 0.0001). There was no
signiﬁcant difference in OS (median OS 12.5 vs. 10.7 months; HR
0.86; 95% CI 0.67–1.11, p= 0.2514). Posttrial systemic treatment
was received by 49% and 63% of patients in the pazopanib and
placebo arms, respectively. Respective best objective responses as
determined by an external review in the pazopanib and placebo
arms were partial response in 6% and 0%, stable disease in 67%
and 38%, and disease progression/death in 24% and 62% of
patients, respectively. Safety and toxicity data were broadly in
keeping with earlier pazopanib studies, with fatigue, hypertension,
diarrhea, and anorexia among infrequently experienced grade 3–4
toxicities. A small excess in decreased left ventricular ejection
fraction, thromboembolic events, and pneumothorax was
observed in the pazopanib arm. One of eight on-treatment deaths
in the pazopanib arm—a patient who died of multiorgan failure—
was possibly related to the study drug. Subsequently, an
exploratory health-related quality-of-life analysis reported that
the scores for general health status did not signiﬁcantly differ
between pazopanib and placebo-treated patients, while speciﬁc
toxicity-related measures related to diarrhea, anorexia, nausea,
fatigue, and role functioning favored the placebo20.
A subsequent post hoc analysis of the Japanese subcohort from
the PALETTE study (n= 47) demonstrated similar levels of PFS and
OS beneﬁt to the overall study population21. There was no overall
difference in the type or severity of pazopanib-related toxicity
within the Japanese subcohort and overall study population,
although a higher rate of dose reduction and lower average daily
dose was experienced by Japanese patients. The lower pazopanib
exposure but equivalent efﬁcacy seen in the Japanese cohort
potentially suggests contrasting PK proﬁles between different
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ethnic groups. However, given that pazopanib dose reduction
within these trials was at investigator discretion, it is possible that
the more frequent dose reductions reﬂect regional variations in
practice. A similar comparison of TKI safety in patients with mRCC
treated in an RCT with pazopanib or sunitinib reported similar
levels of drug exposure but a distinct pattern and severity of
adverse events in Asian versus non-Asian subgroups22. Meanwhile,
a phase I study of pazopanib in a Japanese population reported a
similar PK proﬁle to the initial phase I23. Although these data do
not provide a consistent picture of ethnic and geographical
variation in the PK and PD proﬁle of pazopanib, recognized
differences in the metabolism of many cancer and noncancer
drugs between different ethnic groups indicate the potential for
ethnic background to contribute to interindividual variation in
pazopanib exposure and toxicity24,25.
A further post hoc subgroup analysis of data from the PALETTE
trial, in combination with data from the preceding phase II,
focused on patients with uterine sarcomas treated with pazopanib
(n= 44, 88.6% LMS, 84.1% high grade)26. Compared to patients
with uterine sarcomas who received placebo within the PALETTE
study, patients randomized to pazopanib had a signiﬁcantly
longer median PFS (3.0 vs. 0.8 m, p < 0.001) and median OS (17.5
vs. 7.9 m, p= 0.038).
The results from the PALETTE study were taken to reﬂect a
clinically meaningful level of activity and beneﬁt from pazopanib
in the eligible population, leading to the drug receiving a license
for use in pretreated advanced STS of non-LPS subtypes in the US
and Europe in 2012. The subgroup analyses indicated that the
efﬁcacy and safety proﬁle of pazopanib is similar in Japanese and
non-Japanese populations and that the efﬁcacy in uterine
sarcomas is broadly equivalent to that in nonuterine sarcomas.
Other clinical evidence of pazopanib effect in STSs
Several other prospective and retrospective series provide
additional evidence for the efﬁcacy of pazopanib, both in
unselected cohorts of mixed histological subtype, as well as
diagnosis-speciﬁc series with a variable focus on epithelioid
sarcoma, SFT, DSRCT, chondrosarcomas, and vascular sarcomas. In
addition, data have been reported for 211 patients of mixed STS
subtypes treated with pazopanib in an international expanded
access program that was conducted following the PALETTE trial27.
The efﬁcacy data from these studies are summarized in Table 1
and broadly conform to those from the PALETTE study, with
infrequent objective responses seen and median PFS and OS
values following the start of pazopanib of ~3–5 and
~10–14 months, respectively. Of note is a prospective single arm
phase II study that provides further information on the efﬁcacy of
pazopanib in LPS28. Opening following the reporting of the results
of the PALETTE study and noting the results of the antecedent
phase II where efﬁcacy of pazopanib in the ﬁnal, centrally
conﬁrmed LPS cut-off was in fact above the predetermined futility
cut-off. This multicenter US study treated 41 patients with
intermediate or high-grade LPS with pazopanib and reported a
12wPFR of 60%. The median PFS and OS (4.4 and 12.6 months,
respectively) were consistent with efﬁcacy data for other STS
subtypes from the PALETTE study. However, particularly given that
the EORTC pazopanib phase II study did not distinguish between
the clinical and biological diversity encompassed within the
principle LPS subtypes29, the precise role of pazopanib and other
antiangiogenic agents in LPSs remains to be deﬁned.
In an attempt to improve the generally modest activity of
pazopanib in unselected advanced STS, a number of reported and
ongoing trials have investigated the combination of the drug with
various cytotoxic chemotherapy regimens or targeted agents,
such as histone deacetylase inhibitors30–33. While several of these
combinations have been associated with unacceptable toxicity
and/or insufﬁcient activity in phase I studies, others have
progressed to examining efﬁcacy in STS-enriched cohorts. Due
to the lack of convincing evidence of incremental activity of such
combinations, further detail of these studies is not explored in this
review.
EVIDENCE OF BIOMARKERS OF PAZOPANIB EFFECT
The effect of pazopanib in STS is evidenced by the improvement in
PFS without associated deterioration in quality of life compared to
placebo in a randomized phase III study, as well as reports of
postapproval experience in ‘real world’ settings. However, the
beneﬁt of pazopanib treatment to individual patients is highly
variable and, in the context of infrequent objective tumor
responses, often difﬁcult to conﬁrm. Furthermore, despite the
RCT evidence of an antitumor effect in an otherwise poor-
prognosis patient group with limited treatment options, no
signiﬁcant difference in OS was seen between pazopanib-treated
and placebo-treated patients. It has not been established why a
signiﬁcant PFS gain did not translate into an OS beneﬁt; proposed
explanations have included a lack of statistical power, the
confounding effect of subsequent posttrial treatments or a
potential ‘rebound’ effect, wherein initial treatment with pazopanib
may select for or induce a more aggressive subsequent phenotype
or, alternatively, where accelerated progression is encountered
after the cessation of treatment34–36. The absence of a demon-
strated OS beneﬁt in an unselected STS population has adversely
affected cost-effectiveness appraisals of pazopanib, resulting in
limited access to the drug in several health economies7–9. The
ability to prospectively identify patients with advanced STS who
are most likely to beneﬁt from pazopanib would aid clinical
decision making, increase the clinical and cost-effectiveness of the
drug and improve patient experience and survival outcomes.
However, as summarized below and in Table 2, no routinely
recorded clinicopathological parameters or experimental assays
have yet been shown to be consistently capable of discriminating
between patients with a higher or lower chance of beneﬁting from
pazopanib.
Clinicopathological parameters
Preplanned and post hoc analyses of the EORTC phase II and III
trials of pazopanib have been performed in an attempt to identify
patient or tumor characteristics that enrich for drug beneﬁt. As
discussed above, LPS was identiﬁed as a potentially insensitive
histological subtype within the phase II study, but subsequent
analysis and other studies call into question whether there are
subsets of patients with LPS who may respond to treatment18.
Within the PALETTE study cohort, multivariate analysis identiﬁed
good performance status and lower histological grade as factors
associated with improved outcome, both of which are well-
established prognostic factors in STS regardless of pazopanib
exposure6. Predictive analysis did not detect a signiﬁcant
interaction between histological subtype and pazopanib beneﬁt,
with improved PFS with pazopanib vs. placebo seen in all three
histological subgroups (LMS, SS, other). Other baseline character-
istics, including gender, ethnicity, and extent of prior treatment,
were not found to be predictive for OS37.
Patients who received pazopanib within the EORTC phase II and
phase III trials and who met PALETTE-eligibility criteria (i.e., non-
adipocytic histology, measurable disease, adequate organ func-
tion, etc.) (n= 344) were included in a retrospective analysis that
sought to identify baseline factors associated with a good
outcome following treatment38. Here, the authors deﬁned PFS ≥
6 months and OS ≥ 18 months as long-term response and survival,
respectively, with 36% of patients showing long-term response,
34% showing long-term survival, and 22% showing both long-
term response and survival. Descriptive and multivariate analyses
again identiﬁed tumor grade and performance status as having
prognostic relevance for PFS and OS, as was the case with baseline
hemoglobin levels. There was no preponderance for any
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histological subgroup in the long-term responder or survivor
patient groups. These ﬁndings, consistent with results from other
case series summarized in Table 1, indicate that a proportion of
patients across many different STS subtypes obtain a signiﬁcant
beneﬁt from pazopanib.
Radiological biomarkers
Data from the PALETTE study indicate that the PFS gain seen with
pazopanib is associated with a minor increase in the rate of
radiological objective response compared to placebo (6% vs. 0%)
but a much larger increase in stable disease rates (67% vs. 38%)6.
This ﬁnding implies that pazopanib beneﬁt was predominantly
associated with disease stabilization rather than signiﬁcant tumor
shrinkage. However, given that over one-third of patients who
received placebo also exhibited stable disease as the best
response, the difﬁculty in discerning intrinsically indolent but
pazopanib-resistant disease versus true pazopanib-related tumor
stabilization presents a clinical challenge when attempting to
appraise early signs of beneﬁt to individual patients. The use of
imaging modalities that provide information on changes in tumor
physiology beyond a dimensional response shows promise for
assessing pazopanib effect and represents a potential avenue of
delineating the heterogeneity of tumor response within the
RECIST category of stable disease. Since responding sarcomas can
undergo a decrease in tumor blood supply and consequent cystic
degeneration, potentially with an associated increase in tumor
dimension due to resulting inﬂammation, the measurement of
changes in tumor vascularity as a proxy for antitumour effect has
been pursued. The initial pazopanib phase I trial used DCE-MRI to
measure changes in tumor vascularity in a subset of pazopanib-
treated patients. Further investigation of this functional MRI
modality is required to assess the adequacy of detected vascular
alterations as surrogates for survival endpoints. Computerized
tomography (CT)-based criteria that account for a reduction in
tumor density that reﬂects tumor cell death have been developed
by Choi et al.39. These criteria have been demonstrated to be more
sensitive for TKI beneﬁt than RECIST criteria in GIST and have
shown promise for other STS subtypes in terms of speciﬁcity in
predicting pathological response and favorable outcome in
patients treated with cytotoxic chemotherapy40–42. Durable
disease control with pazopanib has been reported in patients
with SFT who had SD as the best response by RECIST but PR by
Choi criteria43,44. Following these observations, a prospective,
single arm phase II trial of pazopanib in advanced SFT performed
at centers in Italy, France, and Spain assessed the overall response
by Choi criteria as its primary endpoint45. Objective responses by
Choi criteria were seen in 18/35 (51%) of treated patients,
compared to 2/35 (6%) by RECIST. While Choi criteria and RECIST-
based nonprogressing patients exhibited similarly favorable OS,
Choi criteria were better than RECIST for identifying patients with
progressive disease (PrD) and poor OS (median OS of 4.5 vs.
6.5 months in the Choi PrD and RECIST PrD groups, respectively),
and the median OS in patients identiﬁed as PrD by RECIST but PR
by Choi was 24 months. These data suggest that Choi criteria may
better discriminate between patients with or without beneﬁcial
responses to pazopanib in the treatment of SFT. Further
information on the utility of Choi criteria, as well as functional
MRI and ﬂuorodeoxyglucose positron emission tomography (FDG-
PET), in predicting pazopanib beneﬁt will be provided by a now-
completed window-of-opportunity study of preoperative treat-
ment in localized STS (NCT01543802)46. The potential utility of
FDG-PET-CT in this scenario is also informed by small studies that
have demonstrated an association with either a decreased
maximum standardized uptake value (SUVmax) during therapy
and durable disease control or the absence of a SUVmax response
and lack of clinical beneﬁt47,48. Given that Choi criteria, PET-CT,
and functional MRI lack validation in this setting and face issues of
interobserver reproducibility, further development of these
imaging approaches as a tool for accurate early detection of
pazopanib beneﬁt is required. However, these modalities remain
promising avenues for distinguishing between responding
patients who are likely to beneﬁt from ongoing therapy and
those without a response who would be better served by a
change of therapy.
Markers of drug exposure
Numerous PK factors can inﬂuence systemic drug exposure,
including oral absorption and metabolism, drug–drug interactions,
food–drug interactions and patient characteristics such as age,
gender, and bodyweight, which may be related to variations in the
volume of distribution. As such, high interpatient variability of
plasma exposure to oral anticancer drugs, including pazopanib,
may affect drug efﬁcacy and treatment outcome. Retrospective
analyses of clinical trial data on the use of pazopanib in the
Table 2. Candidate biomarkers investigated for association with the pazopanib effect in advanced STS
Candidate biomarker Reported association
Baseline clinico-pathological characteristics
Histological subtype •Lower 12wPFR in LPS compared to LMS, SS and heterogeneous ‘other’ subtypes18
•No enrichment for particular subtype in long-term responders and/or survivors38
Performance status 0
Low histological grade
•Favorable PFS and OS6,38
Radiological markers •Possible superiority of Choi criteria and/or FDG-PET over RECIST 1.1 in categorizing stable disease47,48
Pharmacodynamic markers
Hypertension •No association of hypertension with improved PFS or OS in post-hoc analysis of aggregated phase II/
III data52
Other on-target toxic effects •No association of drug-induced proteinuria, hypothyroidism or cardiotoxicity with improved PFS or
OS in post-hoc analysis of aggregated phase II/III data54
Concomitant gastric acid
suppression (GAS)
•Signiﬁcantly inferior PFS (HR1.49, 95% CI 1.11–1.99, p= 0.008) and OS (HR 1.81, 95% CI 1.31–2.49,
p < 0.001) among pazopanib-treated patients who received concomitant GAS56
Baseline biological markers
Circulating angiogenic factors •Association with worse PFS in single study—requires validation61
Circulating neutrophil-to-lymphocyte ratio •Raised ratio acts asf a poor prognostic marker but not predictive for pazopanib effect63,64
Tumor TP53 mutation •Association between NGS-detected TP53 mutation and improved PFS with pazopanib—single small
retrospective study65
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treatment of mRCC and advanced GIST have reported associations
between higher trough levels of plasma pazopanib concentration
and longer PFS49,50, giving rise to the possibility that variability in
drug exposure levels may, at least in part, explain the variability in
outcome in pazopanib treatment of advanced STS. A prospective
cohort study of patients with mRCC or advanced STS/GIST treated
with TKIs including pazopanib demonstrated that dose optimiza-
tion in response to suboptimal trough drug levels was successful
in attaining subsequent adequate trough levels, indicating that
dose monitoring and adjustment could represent a path to
improved clinical effectiveness of these drugs51.
Hypertension is a frequently occurring on-target side effect of
pazopanib and correlates with the PK degree of drug exposure. As
such, the use of hypertension as a biomarker for adequate drug
dosing and/or treatment effect has been pursued. However, as has
been seen with the use of pazopanib in mRCC, the combined
analysis of prospective patient data from the EORTC phase II and
phase III trials has indicated that the development of hypertension
during pazopanib therapy is not associated with improved PFS or
OS52,53. A later analysis of other on-target toxicities within the
same cohort found no association between the incidence of drug-
induced proteinuria, hypothyroidism, or cardiotoxicity with
survival54. These ﬁndings are consistent with data from a single
center 26-patient case series that found no signiﬁcant association
between suboptimal trough levels of pazopanib and worse PFS
following treatment, indicating that drug exposure alone is unable
to account for variation in pazopanib effect55.
In light of the established PK effect of gastric acid suppression
(GAS) on many anticancer TKIs, including pazopanib, Mir et al.
recently reported a further analysis of the EORTC trial cohorts that
investigated a possible association between the concomitant use
of proton pump inhibitors or histamine H2-receptor antagonists
and pazopanib efﬁcacy56. They found that patients who were
coadministered GAS for >80% of the duration of their pazopanib
therapy had signiﬁcantly shorter PFS and OS compared to patients
who received pazopanib and took either no or less frequent
concomitant GAS. These associations were found to be indepen-
dent of other prognostic factors by multivariate Cox analyses. No
association between GAS and survival outcome was found in
patients who received placebo, suggesting a causative interaction
between GAS use and reduced beneﬁt from pazopanib. However,
such conclusions should be tempered by the limitations of the
post hoc, retrospective design of this study, wherein correlative PK
data were not available, no formal testing for an interaction
between GAS exposure and pazopanib beneﬁt compared to
placebo was performed, and no association between GAS use and
on-target pazopanib toxic effects was observed.
Baseline biological markers
Due to the inhibitory activity of pazopanib against a number of
molecular mediators of tumor angiogenesis and the relative ease
of using multiplexed antibody-based assays to assess for protein
levels in blood, biomarker research has so far largely focused on
investigating circulating angiogenic factors (CAFs). This is espe-
cially true in mRCC, a disease where dysregulated angiogenic
pathways are known to contribute signiﬁcantly to tumor
development, and for which pazopanib and other TKIs that target
angiogenic mediators are established standards of care. These
studies have identiﬁed a varying repertoire of CAFs or cytokines
whose baseline level or change in response to therapy have been
associated with differential outcomes following TKI therapy57.
However, the retrospective nature of many of these studies and
the lack of interaction between biomarker and treatment effects in
prospective studies have limited the extent to which such
investigations inform the search for predictive, rather than
prognostic, biomarkers for pazopanib. An exception to this
situation was seen in the analysis of prospectively collected
pretreatment blood samples taken from patients with mRCC
treated in either a noncomparative phase II or randomized phase
III study of pazopanib58. After initially screening for the association
of 17 CAFS with outcome in the phase II cohort, seven candidates
were then taken forward for validation in the phase III cohort.
Among these, interleukin-8 (IL-8) and osteopontin were validated
as negative prognostic, but not predictive, biomarkers for PFS.
However, the effect of interleukin-6 (IL-6) levels on post pazopanib
outcome was shown to signiﬁcantly interact with pazopanib
exposure, indicating that while patients with an increased baseline
IL-6 had a worse prognosis than those with low IL-6, the former
was the group in which pazopanib treatment delivered the most
beneﬁt. Despite this high-level evidence for baseline circulating IL-
6 levels for pazopanib in mRCC, this biomarker has not impacted
routine practice so far, for reasons that include the limited
analytical replicability of IL-6 assays and the lack of validation in an
independent prospective cohort. Other studies have investigated
tumor-based pazopanib biomarkers, including retrospective
assessment of gene expression-based mRCC molecular subgroups,
hypoxia-inducible factor (HIF) levels or von Hippel–Lindau tumor
suppressor gene (VHL) mutational status in tissue series. These
studies have indicated prognostic associations of the investigated
markers, but due to their retrospective design and lack of
validation, their predictive utility remain unproven59,60.
Several studies have reported baseline biomarkers with putative
predictive associations with pazopanib efﬁcacy in advanced STS
patients. Sleijfer et al. examined the serum levels of cytokine and
angiogenic factors in a cohort of 85 patients from the EORTC
phase II trial and demonstrated that increased baseline plasma
levels of proangiogenic hepatocyte growth factor (HGF) and basic
nerve growth factor (bNGF) were associated with worse PFS in
pazopanib-treated patients61. These ﬁndings are consistent with
the role of pazopanib as an antiangiogenic agent and an
association of various CAFs with poor post pazopanib survival,
but the impact of the study is limited by high reported false
discovery rates combined with lack of validation in independent
cohorts.
The ratio of neutrophils to lymphocytes (NLR) in the circulation
of patients can serve as an easy-to-measure marker of systemic
inﬂammatory state in cancer patients. High NLR has been shown
to be a negative prognostic marker in multiple solid tumor
types62. Blood samples collected at pretreatment baseline and
after 50 days of therapy were used to assess the association
between NLR and pazopanib outcome in 333 patients treated with
pazopanib within the EORTC phase II and III studies63. While
elevated NLR at baseline was a poor prognostic marker regardless
of treatment with pazopanib or placebo, no observed pattern of
change in NLR between baseline and Day 50 (stable, >40%
increase or decrease) was seen to have any association with PFS or
OS. In contrast, in a smaller study of 25 patients treated with
pazopanib in several Japanese centers, a decrease in NLR from
baseline to Week 4 of therapy showed a highly signiﬁcant
association with improved PFS, while baseline NLR had no
prognostic association64. This study used a higher cut-off to
deﬁne high and low NLR patients (based on the cohort median
NLR value) and did not provide a deﬁnition as to what constituted
a signiﬁcant change in NLR during therapy, potentially contribut-
ing to the discrepancy with the EORTC cohort analysis. Regardless,
beyond the consistently observed prognostic association of NLR in
STS and other cancers, its role as a potential predictive biomarker
for pazopanib appears to have little promise.
In a study by Koehler et al. next-generation sequencing (NGS)
was used to sequence 405 cancer-related genes in pretreatment
tumor samples from a retrospective cohort of 19 patients with
advanced STS treated with antiangiogenic agents (18 pazopanib
and 1 sunitinib)65. TP53 and RB1 were the only two genes found to
be altered in >20% (in 10 and 6 patients, respectively), with all
detected mutations of TP53 predicted to confer loss-of-function
(missense mutation of DNA binding and/or tetramerization
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domain, or homozygous deletion). While RB1 mutational status
had no association with post-pazopanib outcome, patients with
TP53-mutated tumors were shown to have signiﬁcantly longer PFS
than those with TP53 wild-type tumors. These data represent the
only currently reported tumor-based candidate biomarker for
pazopanib in advanced STS and have yet to be validated. The
biological basis of any association between TP53 function and
pazopanib response remains to be determined.
Preclinical evidence of markers of pazopanib sensitivity and
resistance
Given that pazopanib selectively inhibits several growth-promoting
RTKs, the expression levels of these targets in tumor cells are also
attractive candidates for evaluation as predictive biomarkers. While
translational studies of tumor-based expression of RTKs in
pazopanib-treated STS are lacking, several preclinical studies have
assessed the association between RTK expression and pazopanib
effect. In one such study, screening of 14 cell lines representing
eight different sarcoma subtypes identiﬁed that only the two
malignant rhabdoid tumor (MRT) cell lines displayed pazopanib
sensitivity66. These cell lines were shown to express phosphory-
lated PDGFRA and FGFR1, both kinase targets of pazopanib. Dual
pharmacological inhibition or genetic silencing using RNA inter-
ference (RNAi) of these targets led to a synergistic increase in
tumor cell apoptosis. Acquired pazopanib resistance was then
derived in these cells through culture in the presence of an
escalating drug dose. Comparison of molecular proﬁles between
parental and resistant cell lines identiﬁed signiﬁcant downregula-
tion of PDGFRA but maintenance of FGFR1 expression and
activation. These cells were no longer dependent upon PDGFRA
signaling but remained sensitive to FGFR1 inhibition, indicating
that loss of PDGFRA could serve as a marker of acquired pazopanib
resistance that could potentially be therapeutically targeted with
inhibitors of FGFR1. In a follow-up study, further comparative mass
spectrometry-based phosphoproteomic characterization of these
paired pazopanib-sensitive and pazopanib-resistant cells identiﬁed
increased activity in cytoskeletal regulatory pathways and down-
regulation of histone deacetylase activity in pazopanib-resistant
cells67. Elsewhere, immunoblot and antibody array-based
comparative proteomic proﬁling was performed on four different
synovial cell lines, three of which were sensitive to pazopanib, with
the other showing primary pazopanib resistance68. Increased
expression of PDGFRB and phospho-activation of tyrosine kinases,
including FGFR3 and VEGFR1, were shown to be unique to the
resistant cell line, while RNAi-mediated silencing of PDGFRB, MET,
and protein tyrosine kinase 2 beta (PTK2B) reduced viability of the
pazopanib-resistant cells. Collectively, these studies indicate that
the relative pazopanib sensitivity of sarcoma cells is reﬂected and
possibly determined by differential expression and phosphoryla-
tion of RTKs and downstream pathway signaling proteins. While
translational correlates of these preclinical ﬁndings are lacking,
there is an indication that investigating the expression levels of
molecular targets of pazopanib within tumor tissue may yet
identify biomarkers for drug effect.
CONCLUSIONS AND FUTURE DIRECTIONS
The successful clinical development of pazopanib as a treatment
for advanced STS has addressed the longstanding and ongoing
need for effective novel agents for these rare diseases. However,
reported clinical trial data indicate that only a minority of patients
within the indicated STS population will receive beneﬁt from
treatment and that the duration of beneﬁt may in many cases be
short. Reported data from subgroup analyses of prospective
pazopanib studies have so far failed to identify baseline
clinicopathological characteristics that enrich for pazopanib
beneﬁt. Moreover, the small number of translational studies that
have investigated circulating or tumor-based biomarkers have yet
to provide reproducible and validated candidate biomarkers. A
growing volume of biomolecular proﬁling data indicate the
existence of biological intrinsic subgroups within individual STS
histotypes. In addition, biological traits such as increased
chromosomal instability can be demonstrated in a proportion of
tumors across multiple STS subtypes and are associated with
shared clinical phenotypes69–71. Assessment for differential treat-
ment outcomes between such biologically classiﬁed STS sub-
groups within pazopanib-treated cohorts represents a worthwhile
avenue for biomarker research.
The further development and validation of putative imaging
surrogate markers for survival would provide better discriminatory
trial endpoints and assist in the early detection of clinical effects.
At present, it is unclear by what precise mechanism or
mechanisms pazopanib exerts its anticancer effect in STS and
whether this effect varies between and within different STS
subtypes.
Furthermore, even in patients showing an unequivocal initial
beneﬁt from treatment, the development of pazopanib resistance
is ubiquitous. A greater understanding of the mechanisms of drug
effect and primary and secondary drug resistance is required to
inform patient selection and the development of novel combina-
torial regimens in which pazopanib might be paired with other
small molecule inhibitors, cytotoxic drugs, or potential immu-
notherapeutic approaches. A greater degree of preclinical and
translational research is required to reveal the therapeutic and
resistance mechanisms of pazopanib in disease-speciﬁc contexts.
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